Go back to some of my old posts about patent bundling. A customer may take a license that includes their entire patent portfolio, where if you want the recent IP, you re-license the older IP. Maybe they pay a reduced rate on the older IP. I'm sure a licensee can negotiate terms based on need, but the idea that once the patents expire there is no revenue left is likely inaccurate. Is it affected? Most definitely, and eventually it may go to zero but not right away. The advantage of the CSP patents were that they used existing infrastructure so there are probably minimal trade secrets there but the process itself is most certainly confidential.
The obvious reason would be that their machinery and processes for CSP incorporate licensed trade secrets in addition to the patents.
If they can go owned-proprietary (or a different IP supplier) for new generation increased-density packaging, then the royalties on the outgoing technology will be small. If they can't, being on good terms with Tessera will make licensing microPILR easier.
This is good news, but not the sort of thing that sets off a big price move.
Can you please give a target price you see by the end of 12/31/10.
Then, we can see if it comes true, or what caused the reversal.
TSRA can go either way, but has more negative than positive news and earnings not a factor to move the stock price. Easily can see 10 or 20.
25 from here looks like a stretch; patents don't last forever might be the fear TSRA can't head higher? What news will move TSRA higher?
I'm sure this info is just as valuable as Bad.gnome, so what should I do now??? I'm so confused... With so much in depth knowledge being posted to the board what's an analyst to do?